세계의 장질환 검사 시장 규모는 2024년 43억 1,000만 달러에 달할 것으로 예측됩니다. 향후 IMARC Group은 이 시장이 2033년까지 56억 4,000만 달러에 달할 것으로 예상하며, 2025-2033년 2.90%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측했습니다. 현재 아시아태평양이 시장을 독점하고 있으며, 2024년 시장 점유율은 38.8%를 초과할 것으로 예측됩니다. 장질환 검사 시장 점유율은 소화기 감염 발생률 증가, 조기 진단에 대한 인식 증가, 진단 기술의 발전, 더 빠르고 정확한 검사 방법에 대한 수요 증가, 식품 및 물 안전 기준에 대한 전 세계 관심 증가로 인해 확대되고 있습니다.
장질환 검사 시장의 성장은 소화기 감염 및 식중독 증가, 진단 기술의 발달로 인해 증가하고 있습니다. 박테리아, 바이러스, 기생충에 의한 장질환은 전 세계에서 수백만 명이 앓고 있으며, 심각한 설사, 탈수 및 기타 합병증을 유발하고 있습니다. 빠르고 정확하며 비용 효율적인 진단 솔루션에 대한 수요가 증가하면서 시장 확대에 박차를 가하고 있습니다. 식품 안전에 대한 인식이 높아지고, PCR 및 면역 분석과 같은 분자진단과 함께 질병 감시를 위한 정부의 구상은 진단 기업 수요를 촉진하고 있습니다. 진단 기업은 헬스케어 분야의 기술 업그레이드에 힘입어 보다 신속하고 신뢰할 수 있는 신속한 검사 솔루션에 많은 투자를 시작했습니다. 검사실 자동화의 추진은 현장 진료 검사 키트와 함께 시장을 발전시키고 있습니다. 또한 연구센터와 의료기관의 제휴를 통해 진단 제품을 보다 쉽게 접할 수 있게 되었습니다. 또한 조기 및 정확한 진단에 대한 수요 증가는 발병 억제 및 예방에 중요한 요소인 장질환 검사 시장 동향에 지속적으로 영향을 미칠 것입니다.
미국은 장질환 검사의 주요 지역 시장으로 부상하고 있으며, 식중독 환자 증가, 소화기 감염에 대한 인식, 진단 기술의 발전이 그 원동력으로 작용하고 있습니다. PCR과 면역분석을 포함한 분자진단법은 정확하고 빠른 결과를 얻을 수 있으며, 인기를 끌고 있습니다. FDA의 식품안전현대화법(FSMA)과 같은 정부의 구상은 예방 조치와 조기 발견에 중점을 두어 시장 수요를 더욱 촉진하고 있습니다. 병원, 진단 실험실, 현장 검사실은 진단 자동화 및 AI를 통한 진단 효율화의 주요 최종사용자입니다. 미국 시장의 주요 기업은 첨단이고 합리적인 가격의 검사 솔루션을 출시하기 위해 많은 연구개발 투자를 하고 있습니다. 의료비 및 식품 안전 기준의 강화도 향후 수년간 미국 장질환 검사 시장을 확대할 것으로 예측됩니다.
소화기 감염 발생률 증가
개발도상국을 중심으로 위생 환경의 부족, 오염된 음식, 물로 인한 위장병 발생률 증가, 놀라울 정도로 높은 인구 밀도로 인해 장질환 검사에 대한 수요가 증가하고 있습니다. 2024년 타임즈 오브 인디아의 기사에 따르면 벵갈루루에서는 오염된 수자원과 불충분한 위생 환경으로 인해 위장병이 증가하고 있다고 합니다. 설사로 인해 탈수 위험이 있는 아이들에게는 설사 중 우유를 피해야 하지만, ORS는 필수적입니다. 세계보건기구(WHO)에 따르면 전 세계에서 설사로만 약 150만 명이 사망하고 있습니다. 특히 개발도상국의 5세 미만 어린이들은 설사, 구토, 사망, 영양실조에 시달리고 있습니다. 이것이 장질환 검사 시장의 가치를 더욱 크게 높이고 있습니다.
정부 및 규제 활동
정부와 보건기관이 엄격한 식품 및 물 안전 기준을 도입하고 공중보건 인프라에 투자하면서 공중보건 인프라가 증가하고 있습니다. 이는 발병을 예방하고 대중을 보호하기 위해 빈번하고 효과적인 장질환 검사의 필요성을 더욱 부추겨 시장을 더욱 촉진하고 있습니다. 예를 들어 인도 식품안전기준청(FSSAI)은 2024년 4월 델리 식품안전국과 공동으로 수도의 주요 시장을 대상으로 대대적인 인식 개선 및 계몽 캠페인을 시작했습니다. 마찬가지로 NHM은 모디 정부의 또 다른 주력 프로그램으로 의료 인프라, 필수 의약품 및 진단약, 풀뿌리 수준의 인력 역량 개발에 주력하고 있습니다. 이 모든 것은 환자들이 해외에서 고가의 치료를 받을 필요성을 줄이기 위한 것으로, 향후 수년간 장질환 검사 시장 예측을 높이고 있습니다.
진단 기술의 획기적인 발전
중합효소연쇄반응(PCR), 차세대염기서열분석(NGS) 등 분자진단기술의 발전으로 장내 감염을 신속, 정확, 상세하게 검출할 수 있게 되었습니다. 시장은 더욱 빠르게 확대되고 있습니다. 예를 들어 2023년 8월 ArcticZymes Technologies(AZT)는 신제품 AZtaqTM DNA 중합효소(AZtaqTM DNA polymerase)를 발표했습니다. 중합효소 연쇄반응(PCR) 용도에 사용될 수 있는 프리미엄 내열성 DNA 중합효소는 AZtaqTM이라고 합니다. AZtaqTM는 분자 기기 라인의 논리적 추가를 발표했습니다. 내열성 DNA 중합효소는 PCR에서 중요한 효소이며, 많은 분자진단 및 연구 응용을 가능하게 합니다. 이는 전 세계에서 장질환 검사 시장의 매출을 더욱 증가시키고 있습니다.
The global enteric disease testing market size was valued at USD 4.31 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 5.64 Billion by 2033, exhibiting a CAGR of 2.90% from 2025-2033. Asia Pacific currently dominates the market, holding a market share of over 38.8% in 2024. The enteric disease testing market share is growing due to the increasing incidence of gastrointestinal infections, growing awareness for early diagnosis, advancement in diagnostic technologies, rising demand for faster and accurate testing methods, and increasing global concern for food and water safety standards.
The enteric disease testing market growth is increasing due to the rise of gastrointestinal infections and foodborne diseases and the development of diagnostic technologies. Enteric diseases, caused by bacteria, viruses, and parasites, affect millions worldwide, thereby causing severe diarrhea, dehydration, and other complications. The growth in demand for rapid, accurate, and cost-effective diagnostic solutions is fueling the expansion of the market. Growing awareness about food safety and government initiatives toward disease surveillance coupled with molecular diagnostics such as PCR and immunoassays propel the demand of diagnostic companies, which have begun to invest heavily in faster, more reliable, and quick test solutions, aided by technological upgradation in the healthcare sector. The drive for automation in the laboratory, together with point-of-care testing kits, propels the market ahead. Furthermore, partnerships between research centers and healthcare institutions are making diagnostic products more accessible and available. In addition, increased demand for early and accurate diagnosis will continue to influence the enteric disease testing market trends, an important factor in controlling and preventing outbreaks.
The United States has emerged as a key regional market for enteric disease testing, driven by the increasing cases of foodborne diseases, awareness about gastrointestinal infections, and advances in diagnostic technologies. Molecular diagnostics, which include PCR and immunoassays, are gaining popularity as they are precise and deliver fast results. Government initiatives, for instance, the FDA's Food Safety Modernization Act (FSMA), are further boosting market demand by emphasizing preventive measures and early detection. Hospitals, diagnostic laboratories, and point-of-care testing facilities are major end-users of efficiency through automation and AI in diagnostics. Leading companies in the US market are making significant R&D investments to launch cutting-edge, reasonably priced testing solutions. The cost of health care and the stringency in food safety standards are also expected to increase the U.S. enteric disease testing market over the next few years.
Rising Incidence of Gastrointestinal Infections
With the increasing incidence of gastrointestinal diseases due to lack of sanitation, contaminated food, and water, and the alarmingly high population density, mostly in developing regions, the enteric disease testing demand is increasing. Bengaluru has witnessed a rise in gastrointestinal diseases due to tainted water sources and inadequate sanitation, according to a 2024 Times of India story. While milk should be avoided during illnesses, ORS is essential for children who are in danger of dehydration from diarrhea. According to the WHO, about 1.5 Million people die worldwide due to diarrheal disease alone. Children less than 5 years old in developing countries are being especially struck with diarrhea, vomiting, deaths, and malnutrition. This is further increasing the value of the enteric disease testing market substantially.
Government and regulatory activities
Increasing public health infrastructure is growing as the government and health organizations are introducing stringent food and water safety standards and investing in public health infrastructure. This is further fueling the requirement for frequent and effective enteric disease testing to prevent outbreaks and safeguard the public, which is further boosting the market. For instance, the Food Safety and Standards Authority of India (FSSAI) launched a massive awareness and sensitization campaign in April 2024, that covered key markets in the national capital, in association with the Food Safety Department, Delhi. Likewise, the NHM is another flagship program under the Modi government, which deals with the development of health infrastructure, essential drugs and diagnostics, and human resource capabilities at the grassroots level. All these have been aimed at reducing the patient's need for expensive treatments outside their localities, which in turn is enhancing the enteric disease testing market forecast over the coming years.
Significant advancements in diagnostic technologies
Enteric infections may now be detected quickly, accurately, and thoroughly due to advancements in molecular diagnostics such as polymerase chain reaction (PCR) and next-generation sequencing (NGS). The market is expanding more quickly. For instance, ArcticZymes Technologies (AZT) unveiled AZtaqTM DNA Polymerase, a novel product, in August 2023. A premium thermostable DNA polymerase that may be used in polymerase chain reaction (PCR) applications is called AZtaqTM. introduced the AZtaqTM, a logical addition to the business's line of molecular instruments. The thermostable DNA polymerase is a crucial enzyme in PCR that makes many molecular diagnostic and research applications possible. This is further driving the enteric disease testing market revenue across the globe.
The demand for the reagents and consumables was driven by its need for accurately and efficiently operating diagnostic processes. Repeated testings for pathogens in the gut requires constant stock replenishment for high-quality reagents and consumables. More importantly, rising infectious disease levels and advancements in molecular and rapid testing methods lead to the application of specialized consumables. Increasing governmental grants and the establishment of health infrastructures further promote demand for these core testing supplies. Technological upgrades in the machinery of diagnostic systems, for instance, automated PCR systems, as well as platforms for next-generation sequencing, drive further equipment demands in the market report on enteric disease testing. There is a necessity for high-throughput, reliable, and accurate diagnosis, thereby resulting in an acceptance of highly developed equipment. Additional factors of growing demand include extensive investments in the development of healthcare infrastructure, especially in up-and-coming markets, and investments in laboratory modernization. Additionally, improved disease surveillance programs and public health initiatives boost the market for diagnostic equipment.
Molecular diagnostics techniques hold the leading position in the market fueled by their high accuracy, sensitivity, and faster turnaround times. These techniques, for example, PCR and next-generation sequencing, permit the accurate detection of a diverse range of pathogens, thus further enhancing disease control and outbreak response. For example, Roche announced the launching of the LightCycler(R) PRO System in November 2023, building on the established gold standard technology of the previous LightCycler(R) Systems. This system is designed to increase performance and usability requirements while connecting translational research with in vitro diagnostics. The LightCycler PRO System further enhances Roche's molecular PCR testing portfolio, which features solutions for different practitioners, from conducting research to testing patients who suffer from cancer, infectious diseases, and many more public health challenges. This is further propelling the demand for enteric disease testing globally.
Bacterial enteric diseases represent the largest segment with a share of 48.0%. The high prevalence of infections such as C. difficile, E. coli, and Salmonellosis creates a significant public health risk and drives the demand for enteric disease testing in bacterial types. Rapid, accurate diagnostics are important for effective treatment, outbreak management, and infection control. Testing demand is also fueled by the association of H. pylori with severe gastrointestinal conditions. The increasing foodborne and waterborne outbreaks, stringent food safety regulations, and the need for efficient healthcare interventions further boost the market for bacterial enteric disease testing.
In the hospital diagnostic laboratory, the need for enteric disease testing arises from the urgent necessity for an accurate diagnosis so that proper patient management and treatment can be assured. High patient volumes and the critical nature of diagnosing gastrointestinal infections require reliable and efficient testing protocols. Independent diagnostic laboratories are in demand due to their specialized services and ability to provide rapid, high-volume testing. They are crucial for routine screening, outbreak management, and offering advanced diagnostic techniques, thus meeting the needs of both healthcare providers and patients. This further creates a positive enteric disease testing market outlook. There is a growing concern in academic and research institutes to study enteric pathogens, develop novel detection techniques, and perform epidemiological research, thereby creating an increased demand. Besides, more funds and grants to infectious disease research organizations increase the demand for high-quality and accurate testing capabilities to support scientific activities and public health.
Asia Pacific accounted for a large share of 38.8% for the enteric disease testing market, driven by the increasing incidence rates of gastrointestinal infections due to poor sanitation and hygiene. Rotavirus, Cryptosporidium spp., enterotoxigenic Escherichia coli (ETEC), and Shigella spp. are the primary causes of diarrheal illnesses and deaths, according to new data from the Global Enteric Multicenter Study (GEMS) on the burden and etiology of diarrhea among children living in developing nations. Moreover, norovirus infections, which equally affect adults and children, are the primary source of foodborne disease outbreaks and are responsible for 20% of diarrheal diseases. Consequently, rising awareness about health problems, increasing government efforts in controlling diseases, and better health infrastructure also spur demand. Improved diagnostics and an increased incidence of food and water-borne diseases fuel the growth of the market further. Rapid urbanization and the expanding middle-class population base, with greater access to healthcare, are contributing to the market growth.
The market for North American enteric disease testing is stimulated by strong healthcare infrastructure, advanced diagnostic technologies, and stringent food safety regulations. The CDC and the FDA play a crucial role in disease surveillance and prevention, enforcing strict food and water safety standards. Saliently, the staggering prevalence rates of foodborne illnesses, including Salmonella and Norovirus, drive demand for quick diagnostics. Molecular diagnostics, automation, and AI-based testing are revolutionizing the market. Increased R&D investment along with initiatives of the FDA, such as FSMA, are factors broadening the market's expansion.
The enteric disease testing market in Europe is also expected to grow through stringent food safety laws of the EFSA and rapidly increasing foodborne illness outbreaks. High usage of molecular diagnostics and point-of-care testing is driving the growth of the market. Countries like Germany, the UK, and France are highly investing in diagnostic innovations, improving the efficiency of testing. With the increasing organic and processed food demand, the concern over contamination has increased the demand for rapid and high throughput testing solutions across clinical and food safety sectors.
The Latin American enteric disease testing market is growing due to the rise in foodborne illness cases and the increase in healthcare investments. Poor sanitation conditions and limited water availability are commonly found in numerous regions, increasing the risk for frequent outbreaks due to cholera, E. coli, or rotavirus infection. Governments undertake public health projects, enhance regulatory food safety, and strengthen disease surveillance. Moreover, the growth in private diagnostic laboratory facilities and more affordable rapid-testing kits is creating an opportunity in enteric disease diagnostics, more so in such countries as Brazil, Mexico, and Argentina, as their healthcare is rapidly changing.
In the Middle East and Africa, enteric disease testing demand is increasing due to a high burden of waterborne and foodborne illnesses linked to poor sanitation, contaminated water, and inadequate healthcare access. Diarrheal diseases are a leading cause of mortality, especially in children. Governments and international organizations are focusing on improving disease detection through public health programs and expanded laboratory networks. Growing urbanization, increasing food imports, and significant investments in the healthcare infrastructure further fuel the utilization of modern diagnostic techniques, primarily in Saudi Arabia, South Africa, and the UAE.
United States Enteric Disease Testing Market Analysis
In 2024, the United States held a share of 90.0% of the enteric disease testing market in North America due to emerging outbreaks of foodborne illnesses, a strict regulatory framework, and consumer awareness. According to the Centers for Disease Control and Prevention, millions of infections are produced annually due to foodborne pathogens like Salmonella, E. coli, and Norovirus, and therefore there is a need for sophisticated diagnostic solutions. According to the CDC, each year about 1 in 6 Americans (or 48 Million people) gets sick, 128,000 are hospitalized, and 3,000 die of foodborne diseases. Moreover, the FDA and the USDA have made strict compliance with food safety regulations, and the demand for rapid, accurate testing technologies, including PCR-based and immunoassay methods, is rising. In addition to this, multiplex molecular diagnostics are adopted in increasing numbers with the possibility of detecting more than one pathogen simultaneously at a high specificity. Technology advances, like NGS, improve the identification of pathogens, especially in surveillance and outbreak management. Point-of-care testing is expanding with improvements in early detection in healthcare settings and remote locations. Further, the increasing emergence of antimicrobial-resistant bacteria is motivating more investment in new diagnostic platforms and promoting private-public partnerships between companies, research organizations, and government agencies. Higher healthcare expenditure and insurance coverage for diagnostic testing facilitate early screening and thus contribute to market growth. Additionally, the growing demand for at-home test kits due to e-commerce expansion is shaping the market landscape.
Europe Enteric Disease Testing Market Analysis
Europe's enteric disease testing market is driven by stringent food safety laws, technological advancements, and high public health awareness. The European Food Safety Authority has strict regulations over microbial contamination in food and water, forcing manufacturers and healthcare facilities to employ rapid and reliable diagnostic methods. The increased surveillance of zoonotic diseases and antimicrobial resistance has led to a surge in demand for advanced molecular and immunological testing platforms. Salmonella was the causative agent linked to the highest multi-country foodborne outbreaks reported in the European Union in 2023, at 17 foodborne outbreaks, 81.0% of the total for multi-country foodborne outbreaks, according to the European Union One Health 2023 Zoonoses report. Besides this, the region is experiencing tremendous growth in automated laboratory systems and next-generation sequencing (NGS) techniques, allowing for the accurate identification of enteric pathogens. The increasing number of foodborne infections due to imported food products has enhanced the demand for real-time PCR and multiplex diagnostic assays. Public-private partnerships and European Union-funded projects are promoting research into innovative diagnostic solutions, which in turn is further fueling the growth of the market. Additionally, the growing incidence of traveler's diarrhea, especially due to tourism within and outside the region, is enhancing the demand for portable and rapid testing solutions. In addition, advancing point-of-care diagnostics, integrated with AI-driven data analytics for tracking the disease, also enhances the efficiency of outbreak responses. The market also contributes to the rising integration of diagnostic labs with digital health platforms, improving test access and turnaround time.
Asia Pacific Enteric Disease Testing Market Analysis
Asia Pacific's enteric disease testing market is being propelled by increasing disease burden, rapid urbanization, and improvements in healthcare infrastructure. The region experiences high rates of waterborne and foodborne infections on account of inadequate sanitation and contaminated drinking water. According to studies, an estimated 37.7 Million Indians suffer from waterborne illnesses each year. Salmonella, Vibrio cholerae, rotavirus, and Shigella are still among the major pathogens, and thus, governing agencies are taking measures to strengthen surveillance programs and invest in advanced diagnostic technologies. In addition to this, increasing investments in healthcare, especially in China, India, and Southeast Asian countries, are helping the adoption of automated diagnostic systems for enteric pathogens. The growth rate of the market is being fueled by increasing private laboratories and multinational diagnostic companies, as the PCR-based, ELISA, and microarray platforms are also becoming popular, as they show high accuracy along with rapid results. In addition, technological progress in molecular diagnostics and increased point-of-care testing are making faster and more accurate detection possible. Favorable government initiatives, including India's National Health Mission and China's CDC initiatives, will encourage routine screening. The rising incidence of antimicrobial resistance and emerging zoonotic pathogens are also motivating the development of rapid diagnostic tools, especially in the context of food safety regulations and outbreak response mechanisms.
Latin America Enteric Disease Testing Market Analysis
Latin America's enteric disease testing market is growing owing to frequent waterborne disease outbreaks, improving healthcare infrastructure, and rising government initiatives. Many countries face challenges with unsafe drinking water and inadequate sanitation, leading to high incidence rates of cholera, Shigella, and rotavirus infections. There were around 24,200 suspected cholera cases as of 17 January 2023, as reported in the Latin America & The Caribbean Weekly Situation Update. The region's governing agencies are largely increasing investments in surveillance programs and expanding diagnostic capacities, especially in Brazil, Mexico, and Argentina. In addition, emerging private diagnostic laboratories and collaborations with major global diagnostic firms continue to improve testing availability. Point-of-care and rapid molecular testing technologies are becoming more prevalent, especially in outlying and less privileged regions. Further demand for dependable diagnostic solutions is coming from further strengthened regulations related to food and beverage safety along with increased awareness about antimicrobial resistance. The expansion of public health insurance programs and international funding of infectious disease control are also in support of this market growth.
Middle East and Africa Enteric Disease Testing Market Analysis
The Middle East and Africa's enteric disease testing market is growing due to high disease prevalence, increasing government healthcare spending, and improvements in diagnostic capabilities. Reports indicate that the healthcare expenditure in the Gulf Cooperation Council (GCC) is estimated to be at USD 135.5 Billion by 2027. Water contamination, poor sanitation, and climate-related factors contribute to persistent outbreaks of Cholera, Typhoid fever, and Norovirus. Governments and non-governmental organizations (NGOs) are intensifying efforts to improve water quality and expand disease surveillance programs. Moreover, the adoption of rapid diagnostic kits, particularly in regions with limited laboratory infrastructure, is enhancing early disease detection. Investments in centralized laboratory networks and mobile diagnostic units are improving accessibility in remote areas. In addition to the above, with isothermal amplification-based tests, the advantage of cost and reliability in resource-poor environments is making such technologies more relevant. International partnerships with WHO and UNICEF for infectious diseases are also fueling the need for efficient solutions in enteric disease testing.
The competition in the market for enteric disease testing is highly competitive, wherein the key market players are concentrated on technological advances, strategic collaboration, and geographically expanding markets to strengthen market presence. Major companies such as bioMerieux, Thermo Fisher Scientific, BD, and Abbott are investing heavily in molecular diagnostics, automation, and AI-driven solutions to improve test accuracy and efficiency. One of the significant trends is the development of rapid and point-of-care testing kits, which allows quicker diagnosis and treatment, especially in resource-limited settings. Companies are also integrating next-generation sequencing (NGS) and PCR-based diagnostics to enhance detection capabilities. The market is being shaped by strategic mergers and acquisitions, such as partnerships between diagnostic firms and government agencies to improve disease surveillance. Increasing focus on sustainability and affordability is driving innovation in cost-effective diagnostic solutions, making it more accessible in emerging markets. These efforts are creating a positive enteric disease testing market outlook.